Tolfenamic acid (TFA), a Biopharmaceutics Classification System (BCS) class II drug, exhibits dissolution-limited absorption and significant gastric irritation when administered as conventional immediate-release formulations, limiting its potential for high-dose and long-term applications, including emerging anticancer...
B. P. Dongala, M. Nutan, M. Abdelrahim et al.· International journal of pha...· 0 citations
Current professional guidance supports a cautious distinction between clinical validity and clinical utility: ctDNA can inform prognosis, counseling, and clinical-trial eligibility, but should not routinely replace standard surveillance or independently determine treatment escalation or de-escalation outside evidence-b...
H. Al-Shamsi, S. Rafii, S. Tirmazy et al.· OncoTargets and Therapy· 0 citations
Background: Colon cancer is the fourth most commonly diagnosed cancer worldwide, with elderly individuals accounting for nearly one-third of new cases. While adjuvant chemotherapy has been associated with improved survival outcomes; its effectiveness in elderly patients remains unclear. This retrospective study was con...
Yacob Saleh, Suhaib Khater, T. Alawabdeh et al.· Jordan Medical Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.